Tarsus Pharmaceuticals TARS Cash Flow Statement (2019-2026)

NASDAQ TARS
$73.67 +2.83 (+3.99%)
As of: Nov 10, 2026 · 2:06 PM EST
Reported Financials

Tarsus Pharmaceuticals Quarterly Cash Flow Statement

Periods 29 quarters
Latest Sep 2026

Tarsus Pharmaceuticals reported cash from operations of -$6.00M and free cash flow of -$7.21M for the quarter ended Sep 2026, down 132.9% year over year. This cash flow statement covers 29 quarters of results from Sep 2019 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Operating Activities
Net Income
-14.85M-20.24M-5.74M-22.51M-13.60M-23.42M-31.42M-39.15M-41.90M-35.73M-33.29M-23.42M-23.11M-25.12M-20.34M-12.59M-8.37M-6.97M-18.55M-668.33M
Depreciation and DepletionDep. & Depletion
0.10M0.10M0.10M0.10M0.10M0.20M0.20M0.24M0.20M0.10M0.20M0.20M0.22M0.20M0.20M0.20M0.20M0.80M0.80M
Depreciation, Depletion & Amortization
Amortization of IntangiblesAmort. of Intangibles
0.10M0.10M0.10M0.10M0.24M0.24M0.20M0.20M0.28M0.24M0.20M0.20M
Amortization of Deferred ChargesAmort. Deferred Charges
0.06M0.04M0.05M0.08M0.08M0.03M0.03M0.11M0.11M0.10M0.13M0.14M0.14M0.15M0.15M0.16M0.16M0.17M0.17M
Depreciation & Amortization (CF)Dep. & Amort.
0.04M0.04M0.09M0.09M0.10M0.10M0.18M0.20M0.24M0.20M0.10M0.20M0.20M0.22M0.20M0.20M0.20M0.20M0.80M0.80M
Share-based CompensationStock Comp.
2.18M2.67M3.53M3.58M3.67M3.91M5.19M5.25M5.48M5.52M7.48M7.42M7.40M6.93M8.23M12.24M14.31M11.97M13.29M27.22M
Gains from Sales and DivestituresGains Divest
Gains from Investment SecuritiesGains Investment
0.24M-0.25M-0.26M-0.02M0.02M-0.07M0.02M-0.11M0.42M-0.59M-0.01M2.81M
Other non-cash itemsOther Non-Cash
0.12M0.11M0.11M0.12M0.12M0.17M0.13M0.13M1.94M0.17M0.16M0.14M0.08M0.08M633.84M
Change in Working Capital
Change in ReceivablesChange Receivables
0.02M-0.02M2.50M-2.50M5.36M11.26M13.26M-0.36M-0.37M17.60M15.67M-4.09M14.29M12.44M30.29M-19.32M4.41M
Change in InventoryChange Inventory
0.02M3.09M0.93M0.69M0.65M-0.23M0.08M1.17M-0.04M0.54M0.20M-0.20M0.78M
Change in Accrued ExpensesChange Accrued Exp.
0.36M1.97M-2.10M1.43M1.43M-1.31M0.68M5.81M3.53M12.34M7.09M5.87M12.50M10.17M3.17M24.11M7.94M15.46M13.30M17.45M
Change in Other Operating AssetsOther Assets Change
0.84M-0.72M1.55M2.59M1.00M-3.46M0.87M1.66M2.06M-0.79M-1.42M0.96M7.90M-8.42M23.25M-7.80M-7.47M12.91M-16.76M16.16M
Change in Other Operating LiabilitiesOther Liabilities Change
-0.04M-0.04M-0.03M0.00M0.01M-0.01M-0.03M0.03M0.19M-0.23M0.00M
Other Working Capital ChangesOther WC Changes
-0.87M0.67M-1.58M-2.59M-0.99M3.45M-0.89M-1.62M-1.87M0.56M1.41M-0.96M-7.90M8.42M-23.25M7.80M7.47M-12.91M16.76M-16.16M
Cash from OperationsCash from Ops.
-12.12M-15.29M-4.26M-18.61M-10.87M-21.97M-23.83M-32.36M-39.34M-37.79M-14.40M-8.65M-22.18M-20.65M-29.39M18.26M19.33M-24.65M61.22M-6.00M
Investing Activities
Capital ExpendituresCapex
0.27M0.16M0.12M0.10M0.13M0.34M0.79M0.38M0.17M1.04M0.28M0.07M0.59M1.00M1.91M6.36M5.82M4.07M1.21M
Change in Property, Plant and EquipmentChange in PP&E
-0.27M-0.16M-0.12M-0.10M-0.13M-0.34M-0.79M-0.38M-0.17M-1.04M-0.28M-0.07M-0.59M-1.00M-1.91M-6.36M-5.82M-4.07M-1.21M
Change in IntangiblesChange Intangibless
5.00M
Purchase of InvestmentsInvestments Purchased
57.03M92.41M28.67M0.00M104.55M47.03M21.09M89.97M125.57M129.70M102.33M36.45M126.80M2.40M
Sale and Maturity of InvestmentsInvestments Sold
40.30M64.88M51.74M2.50M10.54M24.50M35.47M91.22M79.00M99.50M92.08M74.06M44.35M72.10M
Cash from Investing ActivitiesCash from Investing
-0.27M-0.16M-0.12M-57.13M-87.22M11.29M64.09M47.37M17.85M-102.22M-40.53M3.13M-59.57M-34.94M-51.70M-4.74M49.27M-58.56M37.88M-189.49M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt IssuancesLT Debt Issuance
20.00M5.00M5.00M75.00M
Net Long-Term Debt Issued (Repaid)Net LT Debt
20.00M5.00M5.00M75.00M
Net Debt Issuances and RepaymentsNet Debt Issuance
20.00M5.00M5.00M75.00M
Change in Capital Stock
Common Stock IssuedStock Issued
0.23M74.81M-0.14M-74.09M0.01M0.51M99.89M-98.84M108.77M2.68M0.68M-95.36M136.56M1.95M2.56M-132.46M1.20M3.30M127.81M
Net Shares Issued and RepurchasedNet Shares Issued
0.23M74.81M-0.14M-74.09M0.01M0.51M99.89M-98.84M108.77M2.68M0.68M-95.36M136.56M1.95M2.56M-132.46M1.20M3.30M127.81M
Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued
Net Equity Issued and RepurchasedNet Equity Issued
0.23M74.81M-0.14M-74.09M0.01M0.51M99.89M-98.84M108.77M2.68M0.68M-95.36M136.56M1.95M2.56M-132.46M1.20M3.30M127.81M
Other financing activities (as filed)
-0.30M-0.88M-0.08M-0.04M
Cash from Financing ActivitiesCash from Financing
-0.07M19.13M74.73M-0.14M0.26M5.01M0.51M104.89M19.76M108.77M42.32M0.64M2.93M136.56M1.95M2.56M2.31M1.20M3.30M127.81M
Additional items
Change in Cash
-12.47M3.68M70.35M-75.87M-97.83M-5.66M40.78M119.90M-1.73M-31.24M-12.61M-4.89M-78.83M80.97M-79.14M16.08M70.92M-82.01M102.40M-67.68M
Ending Cash Balance
171.33M175.01M245.36M169.49M71.66M66.00M106.77M226.67M224.95M193.71M181.10M176.21M97.38M178.35M99.21M115.29M186.20M104.19M206.60M138.91M
Free Cash FlowFCF
-12.40M-15.45M-4.38M-18.71M-11.00M-22.31M-24.61M-32.74M-39.34M-37.96M-15.44M-8.93M-22.25M-21.24M-30.39M16.35M12.97M-30.47M57.15M-7.22M
Net Cash FlowNCF
-12.47M3.68M70.35M-75.87M-97.83M-5.66M40.78M119.90M-1.73M-31.24M-12.61M-4.89M-78.83M80.97M-79.14M16.08M70.92M-82.01M102.40M-67.68M
Interest Paid
0.13M0.97M0.58M0.59M0.71M0.73M0.85M0.87M0.47M4.15M2.17M2.07M2.09M2.12M2.06M1.97M1.99M2.01M
Income Taxes PaidTaxes Paid
1.93M2.84M1.08M

Tarsus Pharmaceuticals Cash Flow Statement API

Pull Tarsus Pharmaceuticals's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=TARS&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY